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Abstract
Well-differentiated hypoxic regions in head and neck squamous cell carcinoma like in A253 xenografts are avas-
cular and, therefore, hinder drug delivery leading to drug resistance and tumor regrowth. Methylselenocysteine
(MSC, 0.2 mg/mouse per day per oral for 35 days starting 7 days before the first irinotecan (CPT-11)) has been
found to increase efficacy of a wide variety of chemotherapeutic agents including CPT-11 (100 mg/kg per week ×
4 intravenously). Whereas CPT-11 leads to a 10% complete response (CR) in A253 xenografts, the combination of
MSC and CPT-11 increased the CR to 70%. Surviving tumors were found to consist largely of avascular hypoxic
regions. Here, we investigated the combination of tirapazamine (TPZ, 70 mg/kg per week intraperitoneal × 4 ad-
ministered 3 or 72 hours before CPT-11), a bioreductive drug in clinical trial with selective toxicity for hypoxic cells,
with MSC and CPT-11 in further enhancing the cure rates. Tumor response, change in tumor hypoxic regions, and
DNA damage were monitored in vivo. Tirapazamine administered 3 hours before CPT-11 in combination with MSC +
CPT-11 led to a lower tumor burden. Tirapazamine did not increase cure rate beyond that of MSC + CPT-11 com-
bination and was instead found to decrease cures with no evidence of an increased DNA damage or a significant
reduction in avascular hypoxic tumor regions. CD31 immunostaining in A253 demonstrated disruption of tumor ves-
sels by TPZ that could lower cytotoxic drug delivery to carbonic anhydrase IX–positive hypoxic tumor cells and may
explain at least partially these unexpected results.
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Introduction
Drug penetration in tumor in therapeutically effective concentra-
tions is hindered by inherent microenvironmental barriers: 1) an in-
creased tumor interstitial fluid pressure (IFP) arising mainly out of
an abnormal tumor vasculature that is morphologically abnormal,
chaotic, dilated with poor perfusion, and that opposes diffusion and
convection—the main form of transvascular transport of therapeutic
agents in tumors both across the blood vessel wall and interstitium
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[1]; 2) tumor hypoxia that lowers tumor cell proliferation, reduces
drug sensitivity, and up-regulates hypoxia-inducible factor 1α—a
transactivator of several tumor survival genes [2,3]; and 3) tumor ac-
idosis that up-regulates carbonic anhydrase IX (CAIX) resulting in a
clinically aggressive drug-resistant phenotype [4]. Heterogeneity in
drug distribution is further accentuated by the presence of avascular,
hypoxic regions that contribute to drug resistance [5]. An ideal mod-
ulator of chemotherapy would enhance the antitumor activity while
diminishing or abrogating chemotherapy induced toxicities, thus
allowing drug dose escalation with the aim of overcoming resistance
to chemotherapy. The naturally occurring amino acid methylseleno-
cysteine (MSC, 0.2 mg/mouse per day × 28 days starting 7 days
before the anticancer drug) has been shown to increase the efficacy
of various chemotherapeutic agents including irinotecan (CPT-11,
100 mg/kg per week i.v. × 4) in head and neck squamous cell car-
cinoma (HNSCC) xenografts—sensitive uniformly poorly differ-
entiated FaDu (from 30% with CPT-11 alone to 100% with the
combination) and in relatively resistant well-differentiated A253
(from 10% with CPT-11 alone to up to 70% with the combination)
[6]. The antiangiogenic effect of MSC contributes to this therapeutic
synergy by normalizing tumor vasculature and reducing tumor IFP,
the net effect of which is to increase drug delivery to the tumor
that was demonstrated for the first time in our recent study [7].
The plasma selenium concentrations seen in preclinical models have
been achieved without any toxicity in humans [8]. Terminally differ-
entiated cells do not proliferate and are thus not a direct concern for
cancer growth and progression. The presence of such differentiated
areas in the well-differentiated HNSCC xenograft increases tumor’s
morphologic heterogeneity, thereby hindering tumor drug distribu-
tion and contributing to chemotherapeutic resistance by allowing
some proliferating Ki67- and CAIX-positive tumor cells in the rim
surrounding well-differentiated avascular regions to escape therapeu-
tically effective concentrations of the drug [5]. An agent that can ab-
rogate these avascular and thus hypoxic tumor regions may increase
chemotherapeutic efficacy.
Tirapazamine (TPZ, 3-amino-1,2,4-benzotriazine 1,4 dioxide, SR
4233) is a bioreductive drug belonging to the aromatic N-oxide family
with selective toxicity for hypoxic cells. In cell suspensions (in vitro),
this selective toxicity of TPZ for hypoxic cells is 50- to 500-fold [9].
Currently, TPZ is in an active phase III clinical trials for comparison
of progression-free survival in stages Ib, IIA, IIB, IIIB, and IVA cer-
vical carcinoma patients treated with cisplatin and radiotherapy with
and without TPZ [10]. Tirapazamine is also in clinical trials with
cisplatin for malignant melanoma and small cell lung cancer with en-
couraging results in phases II and III clinical trials [11,12], whereas
TPZ with or without paclitaxel and carboplatin did not show any
survival benefits in phase III clinical trials with advanced non–small
cell lung cancer [13]. Intracellulary, under hypoxic conditions, TPZ
undergoes one-electron enzymatic reduction by nicotinamide ade-
nine dinucleotide phosphate cytochrome P450 reductase to yield
a transient radical anion that induces the formation of DNA radi-
cals, largely at C4′ on the ribose ring, either directly, or through for-
mation of superoxide leading to both single- and double-stranded
breaks in DNA, resulting in cytotoxicity [14,15]. Sensitivity to
TPZ is enhanced in tumors with CAIX expression [16]. In view of
the results from the recently concluded and ongoing clinical trials,
more preclinical studies are needed to understand the physiologic
mechanism and the impact of TPZ on tumor vasculature, hypoxia,
and cell kill.
The current study was carried out to determine whether TPZ can
abrogate hypoxic regions, and thus, enhance therapeutic efficacy of
CPT-11 and CPT-11 + MSC in the well-differentiated human
HNSCC xenograft A253 growing in nude mice. Further, we report
herewith the implication of the use of TPZ with antiangiogenic
agents such as MSC [7].
Materials and Methods
Tumor Model
The human squamous cell carcinoma cell line A253 was purchased
from American Type Culture Collection (Manassas, VA) and was
established as a solid tumor by injecting s.c. in 10- to 12-week-old
female athymic nude mice (Foxn1nu; Harlan Sprague Dawley, Inc.,
Indianapolis, IN) as described previously [6].Mice were kept in groups
of three to five mice per cage with food and water ad libitum as per a
protocol approved by the Institute Animal Care and Use Committee
at Roswell Park Cancer Institute. Treatment was started when tumor
volumes reached approximately 100 to 250 mm3. Tumor volume
were measured with vernier calipers every other day using the for-
mula: 1/2(L × W 2) (in mm), where L is the longest axis and W is
the shortest axis. Actual tumor volume (ATV) was normalized to
the initial tumor volume (ITV) at the start of CPT-11 treatment as
described earlier [17], that is, median tumor volume % [(ATV /
ITV) × 100]. Tumor response was defined as complete response
(CR) with cure when the tumor was undetectable by palpation, and
no tumor regrowth was observed thereafter for 60 days after the end
of therapy. Mice were killed at the end of the study or when tumor
size exceeded 2 g, whichever was earlier.
Chemotherapeutic Agents
CPT-11 (Pharmacia, Kalamazoo, MI), MSC (Sigma, St. Louis,
MO), and TPZ (Sanofi-Aventis US, Inc., Malvern, PA) were dis-
solved in sterile saline to obtain a final concentration of 20, 1, and
1.4 mg/ml, respectively. The maximum tolerated doses for CPT-11,
TPZ, and MSC were 100 mg/kg (weekly schedule), 70 mg/kg
(weekly schedule), and 0.2 mg/mouse per day, respectively [6,18].
MSC was administered at a dosage of 0.2 mg/mouse per day starting
7 days before the first dose of CPT-11 and continuing for a total of
35 days. Irinotecan was administered i.v. by tail vein at a dosage of
100 mg/kg per week i.v. × 4, whereas TPZ was given i.p. at 70 mg/kg
per week × 4. For the MSC + CPT-11 + TPZ combination therapy,
TPZ was administered before CPT-11 with one group receiving TPZ
at 3 hours and another group at 72 hours beforeCPT-11 administration.
The other groups were TPZ alone, TPZ + MSC, and TPZ + CPT-11,
with TPZ administered 3 hours before CPT-11.
Patient Samples of HNSCC
To determine the clinical relevance of the present study, formalin/
paraffin sections of human surgical samples of well-differentiated
(N = 5) and poorly differentiated (N = 2) HNSCC were studied
for the microvessel distribution using factor VIII (vonWillebrand fac-
tor) and CD34 marker for endothelial cells. Briefly, the primary anti-
body antihuman factor VIII and CD34 (Dako, Carpinteria, CA) were
used at 11.4 μg/ml and 1:50 dilution for 60 and 30 minutes, respec-
tively, at room temperature. Biotinylated goat antirabbit (Vector Lab-
oratories, Burlingame, CA) followed by streptavidin complex (Zymed
Lab, Inc., San Francisco, CA) was used for 30 minutes each.
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Immunohistochemistry
A253 xenografts were harvested 24 hours after the first and third
doses of CPT-11 and were fixed either in zinc or in formalin fixative
for immunohistochemistry as described previously [5]. The methods,
in brief, are as follows:
CD31. Rat antimouse primary antibody CD31 (BD Biosciences
Pharmingen, San Diego, CA) in 10-μg/ml concentration was applied
for 1 hour at room temperature followed by biotinylated secondary
antibody (antirat; BD Biosciences Pharmingen) and streptavidin
complex (Zymed Lab, Inc.) for 30 minutes each.
Involucrin. This keratinocyte differentiation marker is expressed
in the suprabasal layers of normal squamous epithelium and is a
marker for differentiation in human squamous cell carcinomas [10].
Human skin epidermis was used as a known positive (suprabasal
layers) and negative (basal layers) control. The primary monoclonal
antibody (mouse ascites fluid) anti-involucrin clone SY5 (Sigma)
in 16-μg/ml concentration was applied for 1 hour at room temper-
ature. The secondary detection system used was the mouse Envision
kit (Dako).
Ki67. Incubation with mouse antihuman antibody (clone MB67;
Diagnostic Biosystems, Pleasanton, CA) for an hour was followed
by incubation for 30 minutes each with biotinylated secondary anti-
body and streptavidin–peroxidase complex (Thermo Shandon, Pitts-
burgh, PA).
Phosphorylated H2AX. Microwave pretreatment for antigen re-
trieval for a total of 20 minutes in citrate buffer was followed by in-
cubation at room temperature with mouse antihuman monoclonal
antibody (Upstate, Lake Placid, NY) at a concentration of 2 μg/ml
for 60 minutes. Incubation with Elite biotinylated secondary anti-
body (Vector Laboratories) for 30 minutes was followed by Elite
ABC reagent (Vector Laboratories) for 30 minutes.
CAIX. Incubation with M75 antibody (20 μg/ml; a gift from Dr
Pastorek, Institute of Virology, Slovak Academy of Sciences, Slovak
Republic) for 90 minutes at room temperature was followed by
30 minutes of incubation each with Elite biotinylated secondary an-
tibody (Vector Laboratories) and streptavidin complex (Zymed Lab,
Inc.). Quantitation of CAIX-positive tumor cells was carried out in a
light microscope at an original magnification of ×200 using at least
five different regions from each tumor harvested 24 hours after the
first week of CPT-11 administration in the MSC + CPT-11 and
MSC + CPT-11 + TPZ treatment groups to determine the influence
of TPZ in abrogating tumor-hypoxic regions. Individual tumor cells
were counted, and the proportion of CAIX-positive to total tumor
cells was expressed as a percentage of tumor cells that were positive
for CAIX.
In all cases, DAB was used as a chromogen, and nuclear counter-
staining was done with hematoxylin. An isotype-matched negative
control was always used on a duplicate slide in place of the primary
antibody in the same concentration as the primary antibody to con-
trol the specificity of the immunostaining. All histologic and immu-
nohistologic interpretation and quantitation were carried out under
the supervision of a board-certified and experienced pathologist
(Károly Tóth, M.D., Ph.D.).
Statistical Analysis
The differences between the different treatment groups were
analyzed using the two-tailed Student’s t test (Mann-Whitney test)
for significance. A P value ≤ .05 was considered indicative of statis-
tical significance.
Results
Patient Samples of HNSCC
Figure 1 shows representative formalin/paraffin sections from
patient surgical specimens of HNSCC stained for the detection of
intratumoral endothelial cells and microvessel distribution by immu-
nohistochemical method using CD34 antibody. Figure 1, A and B,
shows the normal well-differentiated squamous epithelium of oral
mucosa (arrows), which is avascular (Figure 1A) but not hypoxic,
as evidenced by the negative CAIX staining (Figure 1B). The well-
vascularized poorly differentiated parts of the surgical samples show
the presence of CD34-positive microvessels indicated by arrows in
Figure 1C , and these areas were CAIX-negative, nonhypoxic (Fig-
ure 1D). The well-differentiated part of the tumor cell nests (Figure 1,
WD) were completely avascular; that is, just the surrounding stroma
contained microvessels as indicated by an arrow in Figure 1E . These
areas were hypoxic as demonstrated by the strong membrane-positive
CAIX immunostaining in the tumor cells indicated by arrows in
Figure 1F. These findings, using CD34 as an endothelial cell marker,
demonstrate a morphologic heterogeneity with the presence of avas-
cular tumor regions in human surgical samples similar to that seen in
human HNSCC xenograft A253 used in the current study. Factor
VIII staining results were similar to CD34 with no vessels seen in
the normal epithelium and the well-differentiated regions in the sur-
gical samples.
Antitumor Response in A253 Xenograft
The various drugs used alone or in combination therapy did not
result in any significant weight loss or adverse reaction in the mice.
The tumor volumes (mean ± SD, in mm3, N = sample size) on the
day of first CPT-11 treatment for the various groups were as follows:
untreated control, 243 ± 14 mm3 (N = 5); MSC, 205 ± 15 mm3 (N =
6);MSC +TPZ, 80 ± 22mm3 (N = 8); TPZ, 152 ± 170mm3 (N = 6);
CPT-11, 221 ± 13 mm3 (N = 10); MSC + CPT-11 + TPZ (72 hours
before CPT-11), 90 ± 45 mm3 (N = 29); CPT-11 + TPZ (3 hours
before CPT-11), 213 ± 114 mm3 (N = 6); CPT-11, 221 ± 13 mm3
(N = 10); MSC + CPT-11 + TPZ (3 hours before CPT-11), 111 ±
95 mm3 (N = 22); MSC + CPT-11, 222 ± 12 mm3 (N = 10). Fig-
ure 2 summarizes the percentage median tumor volumes obtained
in A253 with TPZ either alone or in various combinations with
MSC + CPT-11, whereas Figure 3 summarizes the percentage of CR
obtained in the same cohort of mice. Although TPZ administered
alone seem to have a significant (P = .0065) tumor growth–inhibitory
effect, when used in the combination with MSC, this effect was
seen to have been reversed. CPT-11 alone had a significant (P <
.0001) tumor-inhibitory effect compared to TPZ alone. Tirapazamine
in combination with CPT-11 did not further enhance the tumor-
inhibitory effect of CPT-11 (P = .82). Tirapazamine administered
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3 hours before CPT-11 in combination with MSC + CPT-11 did not
lead to better cures when compared to the MSC + CPT-11 group.
Whereas CPT-11 alone had a CR of 10% (10 ± 14), in combination
with MSC, this increased to 70% (70 ± 14). Tirapazamine in combi-
nation with CPT-11 had 0% CR, whereas in combination with MSC
and CPT-11, where CPT-11 was administered 3 hours after TPZ, a
9% (9 ± 2) CR was obtained. In the TPZ, MSC, and CPT-11 com-
bination where TPZ was administered 72 hours before CPT-11 (N =
29), a response rate of 7% (7 ± 13) CR was obtained.
Effect of TPZ Combination Therapy on Tumor Vessel Integrity
Considerable loss of CD31 immunostaining and a compromised
tumor vascular integrity with necrosis in the immediate surrounding
tumor regions of A253 xenograft was seen in some tumor vessels in
the MSC + TPZ + CPT-11 treatment group 24 hours after the first
CPT-11 dose (Figure 4, arrows; original magnification, ×200). At the
comparable time point, in the MSC + CPT-11–treated A253 xeno-
grafts, tumor blood vessels were found to be intact with lumen lined
by CD31-positive endothelial cells. Tirapazamine was thus found to
exhibit vascular-disrupting properties similar to vascular-disrupting
agents such as 5,6-dimethylxanthenone-4-acetic acid reported earlier
from this laboratory [17].
Effect of Combination Therapy on Tumor Cell Proliferation
and Hypoxia
Figure 5 summarizes the immunohistochemical characterization
of A253 in untreated controls (left column) and in the therapeutic
combination of MSC + TPZ (72 hours before CPT-11) + CPT-11;
24 hours after the first dose of CPT-11 (middle column) and after
the third dose of CPT-11 (right column). The MSC + TPZ (3 hours
before CPT-11) + CPT-11 group showed a similar trend. The xeno-
grafts were analyzed for tumor differentiation [hematoxylin and eosin
(H&E), involucrin], tumor cell proliferation (Ki67), cytotoxic effects
(DNA breaks as evidenced by H2AX staining), and hypoxia status
using the innate hypoxia marker CAIX. Figure 5, A–C, shows the
histologic structure of A253 by H&E staining, whereas Figure 5,
Figure 1. Photomicrographs of human normal oral mucosa, poorly and well-differentiated cancers of patient HNSCC surgical specimen
(left panels, CD34 immunostaining to visualize microvessels; right panels, CAIX immunostaining to visualize tumor-hypoxic regions;
original magnifications, ×200). Normal squamous epithelium (arrow) of oral mucosa in human does not contain any microvessels (A)
and yet is not hypoxic as can be seen by the absence of CAIX staining (B). Poorly differentiated regions of human surgical tumor sam-
ples show the presence of tumor neovasculature (C, arrow) and well-vascularized areas are nonhypoxic as can be seen by the absence
of CAIX staining (D), whereas the well-differentiated (WD) regions of the tumor are completely avascular (E) like the normal epithelium,
but unlike the normal epithelium, are hypoxic as evidenced by the expression of CAIX (F).
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D–F, shows involucrin staining—a marker for differentiation. Approx-
imately 35% of the untreated A253 xenografts (329 ± 198 cells of a
total 881 ± 370 tumor cells per high-power field of ×200) comprises
the avascular hypoxic tumor regions, which increased to up to ∼70%
at 24 hours after the first CPT-11 dose in the MSC + TPZ + CPT-11
combination group (445 ± 261 cells of a total 618 ± 293 tumor cells
per high-power field of ×200). Tirapazamine was expected to target
the hypoxic tumor regions and thereby add to the therapeutic synergy
with CPT-11 and MSC + CPT-11 combination. Tumor hypoxic re-
gions still constitute ∼53% of the total tumor area 24 hours after
the third CPT-11 dose in the same combination group (113 ± 119 cells
of a total 209 ± 174 tumor cells per high-power field of ×200). Ab-
rogation of avascular hypoxic regions by the hypoxia-specific drug
TPZ during the course of therapy should have resulted in a tumor
microenvironment that is morphologically homogeneous and, thus,
conducive for a better and increased tumor drug delivery, distribution,
and therapeutic effect with a reduction of Ki67-proliferating tumor
cells. Figure 5, G–I, shows no significant reduction in proliferating
Ki67-positive tumor cells during the course of therapy in the MSC +
CPT-11 + TPZ combination group. Phosphorylated H2AX is a sur-
rogate marker of DNA damage. The cytotoxic effects of both TPZ and
CPT-11 involve DNA damage that can be detected using this sur-
rogate marker. Untreated A253 tumor show very few cells positive
for this marker (Figure 5J ). An improved therapeutic synergy with
TPZ would have resulted in a significant increase in phosphorylated
H2AX during therapy. Figure 5, K and L, indicates that only a small
proportion of these viable cells was positive for DNA damage as
evidenced by the absence of phosphorylated H2AX over the course
of treatment with the combination using TPZ. Figure 5,M–O, depicts
the hypoxic regions as evidenced by the presence of constitutive and
innate hypoxia marker CAIX. Tirapazamine did not significantly re-
duce the hypoxic regions during the course of the combination ther-
apy. Overall, TPZ was not found to significantly and favorably alter
the histologic markers studied for differentiation, hypoxia, and
DNA damage during the course of the combination therapy, which
Figure 2. Kinetics of growth in A253 xenografts to the various chemotherapeutic combination of CPT-11 at 100 mg/kg per week i.v. × 4,
MSC at 0.2 mg/mouse per day p.o. × 35, and TPZ at 70 mg/kg per week i.p. × 4.
Figure 3. Percentage of CR in A253 xenografts to the various
chemotherapeutic combination of CPT-11 at 100 mg/kg per week
i.v. × 4, MSC at 0.2 mg/mouse per day p.o., and TPZ at 70 mg/kg
per week i.p. × 4.
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is consistent with the lack of efficacy of TPZ in combination therapy in
this study.
Discussion
Tumor vasculature typically consists of morphologically abnormal,
dilated, and chaotic vessels, which contributes to poor overall perfu-
sion that resists blood flow and reduces drug delivery to tumors [1].
The resulting increased and adverse tumor IFP forms a barrier to
transvascular convection and diffusion of therapeutic agents in tu-
mors. This results in the escape of some proliferating tumor cells
from therapy, allowing tumor regrowth and development of resis-
tance. Well-differentiated regions in squamous cell carcinomas, being
avascular, are hypoxic, and thus constitute an additional morphologic
barrier to drug delivery. The heterogeneous distribution of tumor
vasculature in head and neck cancer hinders chemotherapeutic effi-
cacy because suboptimal intratumoral drug delivery and distribution
[19]. Factor VIII and CD34 immunostaining is used to identify en-
dothelial cells. CD34 is more sensitive for staining endothelial cells
involved in tumor neovascularization [20]. Our results indicate the
absence of vessels in the well-differentiated regions of both the nor-
mal epithelium and the well-differentiated regions of human tumor
surgical samples. An earlier report from this group [5] has confirmed
the presence of tumor morphologic heterogeneity, constituted due to
the presence of avascular and hypoxic regions in the HNSCC xeno-
graft A253. In the regions immediately surrounding the avascular
well-differentiated regions, there are proliferating poorly differentiated
tumor cells that are negative for involucrin and positive for Ki67/
CAIX (Figure 5M , arrows) [5]. These proliferating (Ki67-positive)
cells located in the rim surrounding such avascular drug-recalcitrant
regions thus escape chemotherapy [5]. Very few of these cells are
H2AX-positive, confirming the inefficacy of chemotherapeutic drugs
against proliferating cells in these regions. The normal squamous ep-
ithelium (just a few layers of cells) that covers the oral mucosa is avas-
cular (Figure 1A) but not hypoxic (Figure 1B), because the normal
vasculature in the connective tissues under the epithelium provides
sufficient oxygen supply by diffusion. Such avascular regions are
commonly present in most HNSCC patients as shown in the human
surgical samples (Figure 1, E and F ). Terminally differentiated cells,
being a nonproliferative components of the tumor, are not a concern
for tumor growth and metastasis, but by contributing to tumor mi-
croenvironment heterogeneity, they impact negatively on drug de-
livery, and thus limit therapeutic efficacy by providing a sanctuary
to some poorly differentiated proliferating Ki67 and CAIX-positive
tumor cells from chemotherapy. Further, CAIX-positive regions were
also seen within the poorly differentiated regions in surgical human
tumor samples that were not well vascularized, thus adding further
tumor heterogeneity and barriers to therapy. The present study, using
human HNSCC xenograft A253 that represents one of the commonly
seen HNSCC cases in the clinic, was carried out to determine the
potential effects of the hypoxia-specific drug TPZ in improving the
therapeutic efficacy of CPT-11 and the combination of CPT-11
with MSC by abrogating the tumor-hypoxic regions that form bar-
riers to chemotherapy.
We have recently shown that MSC causes tumor vascular matura-
tion, improves vessel functionality, and reduces tumor IFP, thereby
causing increased tumor-specific drug delivery, which results in an
enhanced therapeutic efficacy against HNSCC xenografts [7]. Tira-
pazamine, a hypoxia-targeting drug, has a higher activity against tu-
mor cells expressing CAIX [16], such as A253 xenografts. Carbonic
anhydrase IX is accepted as a hypoxia marker that more accurately
reflects tumor hypoxia compared to the hypoxia-inducible factor 1α.
Tumor cells in A253 xenografts that are positive for pimonidazole
staining were also positive for CAIX [5]. Tirapazamine is currently
in phase III trials on the basis of encouraging results in phases I and
II [13,21–27]. Organoselenium compounds are also in clinical trial,
with early encouraging results demonstrating that selenium concen-
trations in the plasma similar to those seen in the preclinical animal
Figure 4. Microphotographs of CD31 immunostained histologic
sections through A253 xenografts treated with combination che-
motherapy. Vascular-disrupting effects of TPZ is seen in two repre-
sentative areas (A and B, arrow) of A253, 24 hours after week 1 of
CPT-11 dose in the combination therapy of MSC + TPZ, with TPZ
administered 72 hours before CPT-11 (original magnification,
×100). Only some tumor regions show this vascular-disrupting ef-
fect, whereas other vessels show the typical normal vascular ap-
pearance (A, right part). In comparison, the combination treatment
of MSC + CPT-11 did not disrupt tumor vasculature (C, arrow)
24 hours after the first dose of CPT-11 (original magnification, ×100).
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model could be achieved in humans without any adverse effects
[8,28]. Organoselenium compounds have also been used as a suicide
prodrug for conversion to the active metabolite methylselenol using
methioninase gene therapy in the preclinical models [29]. Se-(methyl)-
selenocysteine at its maximum tolerated dose (0.2 mg/mouse per day
per oral starting 7 days before CPT-11 administration and continued
for a total of up to 42 days) in combination with CPT-11 (100 mg/kg
per week i.v. × 4) was found to increase the cure rates in A253 xe-
nografts from 10% with CPT-11 alone to ∼70% with the combina-
tion chemotherapy [6].
As seen in Figure 2, whereas TPZ alone had a significant (P =
.0065) inhibitory effect on tumor growth, MSC reversed the antitu-
mor efficacy of TPZ. Se-(methyl)-selenocysteine, by inducing tumor
vascular maturation, improves vascular functionality causing an in-
creased tumor oxygenation [7], and this could make TPZ markedly
less effective and thus, instead of an additive or synergistic effect, an
antagonistic effect was seen when used in combination with MSC.
The quandary is to improve the delivery of TPZ without simulta-
neously improving delivery of oxygen. Tirapazamine in combination
with CPT-11 did not result in an enhanced tumor growth inhibi-
tion compared to CPT-11 alone. Both CPT-11 and TPZ leads to
DNA double-strand breaks [30], and the combination was not found
to be synergistic. Further, TPZ did not enhance the tumor growth
inhibition and cures of MSC + CPT-11 combination but in fact in-
hibits tumor response seen with the MSC + CPT-11 combination.
Tirapazamine in combination with MSC + CPT-11, administered
either 3 or 72 hours before CPT-11, did not abrogate the CAIX-
and Ki67-expressing cells located adjacent to the avascular, hypoxic,
well-differentiated tumor regions (Figure 5) that we had earlier
shown to be responsible, at least partially, for the tumor’s resistance
to therapy [5]. The absence of phosphorylated H2AX nuclear staining
(Figure 5, K –L) from many poorly differentiated Ki67-positive cells
Figure 5.Microphotographs of sequential histologic sections through untreated control A253 xenografts (left panels) and from the treat-
ment group harvested 24 hours after weeks 1 (middle panels) and 3 (right panels) of the CPT-11 dose in the combination therapy of MSC +
TPZ, with TPZ administered 72 hours before CPT-11 (original magnification, ×100). The H&E stain shows the presence of large, well-
differentiated regions (A–C, arrow). These regions are positive for the differentiation marker involucrin (arrow) immunostaining in the
untreated (D) and the area is increasing after therapy (E, F). The numerous proliferating poorly differentiated cells are indicated by Ki67
immunostaining (G–I, arrow). Only a few of these cells are positive (arrow) for phosphorylated H2AX immunostaining (K, arrow), the
surrogate marker of DNA double-stranded breaks, indicating that the combination therapy did not lead to an increased DNA damage
in the tumor cells. Many of these cells are hypoxic (arrow) as shown by the presence of the membrane protein CAIX immunostaining
(N, O). Necrotic (N) regions in panels (L, O) are false positive for immunostaining.
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(Figure 5, H–I, arrows) within rim regions surrounding the well-
differentiated regions in A253 xenografts is an indicator of insuffi-
cient drug delivery in these regions, similar to our earlier report [5].
Recent reports demonstrate that TPZ damages and renders tumor
vasculature dysfunctional in the center of solid tumors, including
squamous cell carcinoma, possibly through inhibition of nitric oxide
synthase [31,32]. Such dysfunctional vessels become nonperfused,
adversely affecting drug delivery to the tumor. In addition, fluctu-
ating oxygenation required for TPZ efficacy [33] may be absent in
tumor-hypoxic regions due to the vascular dysfunction caused by
TPZ in such regions. Our data in Figure 4 (A and B, arrows) confirm
this tumor vascular-disrupting effects of TPZ. Interestingly, the vessel-
disrupting activity of TPZwas not evident in all tumor vessels and was
seen only in some tumor regions. This could be an outcome of the
existing variable tumor oxygenation levels, which results in TPZ acti-
vation only in certain tumor regions where the oxygen gradient is op-
timal for its activity. Tumor cell kill was evident around the regions
where TPZ was found to disrupt tumor vessels. Thus, adding TPZ
to another chemotherapeutic agent such as CPT-11 may not be syn-
ergistically beneficial. Furthermore, TPZ can act to reverse the effect of
antiangiogenic agents such as MSC, which normalizes tumor vascula-
ture by increasing pericyte coverage [7]. Selenium has antioxidant
properties that can impact cellular redox balance through glutathione
peroxidases, thioredoxin reductase, and reduced glutathione/oxidized
glutathione ratio [34], and MSC could result in scavenging of free
radicals generated by TPZ that is primarily responsible for its cytotoxic
effects. Although TPZ is active on hypoxic cells in vitro where drug
delivery is not an issue, in vivo, the hypoxic regions have very limited
vasculature and oxygen supply. During therapy, such regions have poor
drug delivery with lack of drug response. In addition, TPZ by compro-
mising tumor vascular integrity can further compromise drug delivery
that can explain the inhibition of tumor response in vivo when TPZ
was used.
Tirapazamine is commonly used in cisplatin-based chemora-
diotherapy, but its use remains to be investigated in view of mixed
results. Recently concluded phase III clinical trial in non–small cell
lung cancer has failed to show any improved survival benefits with
TPZ in combination with paclitaxel plus carboplatin [13]. Our pre-
clinical results with human HNSCC xenograft A253 confirm that
use of TPZ with CPT-11 or with an antiangiogenic agent such as
MSC alone or in combination with CPT-11 may be counterproduc-
tive in the HNSCC xenograft A253 and should be approached with
caution in the clinical setting.
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